OpenAI unveils GPT-Rosalind, a reasoning model aimed at drug discovery and genomics
OpenAI introduced GPT-Rosalind on April 16, 2026, a frontier reasoning model aimed at drug discovery, genomics analysis, protein reasoning, and scientific research workflows. The release extends the company’s model lineup into a more specialized scientific use case.









